Cassava Sciences drops on delay for epilepsy study
Cassava Sciences' stock dropped ~14% premarket after announcing a delay in its epilepsy study for simufilam due to FDA concerns. The FDA has placed a full clinical hold on the study pending further information, including additional preclinical data. Cassava aims to address these concerns promptly but no longer expects to start the trial in H1 2026. The company has also phased out its Alzheimer's program for simufilam after a trial setback.
Source: businessinsider The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments